ASRS 2024: Neurotech Pharmaceuticals update on the NT-501 device
July 19th 2024Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals Encapsulated Cell Therapy platform for the potential treatment of Macular Telangiectasia Type 2, with a projected PDUFA goal date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
ASRS 2024: Illuminating subclinical sickle cell activities using dynamic OCT angiography
July 19th 2024Richard B. Rosen, MD, from the New York Eye and Ear Infirmary of Mount Sinai discussed his presentation on sickle cell retinopathy and the measurement with dynamic OCT angiography and quad-fusion adaptive optics imaging at the annual ASRS meeting in Stockholm, Sweden.
ASRS 2024: Diabetic retinopathy lesion types and distribution on ultra-widefield imaging
July 19th 2024Paolo Antonio Silva, MD, discusses his presentation on diabetic retinopathy lesion types and distribution on ultra-widefield imaging and the risk for disease worsening over time at the American Society of Retina Specialists meeting held in Stockholm, Sweden.
ASRS 2024: IOP outcomes following suprachoroidal triamcinolone acetonide in patients with glaucoma
July 19th 2024Danny A. Mammo, MD, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss his presentation on intraocular pressure outcomes following suprachoroidal triamcinolone acetonide in patients with glaucoma at the American Society of Retina Specialists meeting held in Stockholm, Sweden.
ASRS 2024: Results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
July 18th 2024Rishi P. Singh, MD, sat down with Sydney Crago, Editor of Modern Retina, to discuss his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA at the American Society of Retina Specialists meeting held in Stockholm, Sweden.
ASRS 2024: Fas inhibition with ONL1204 for the treatment of geographic atrophy
July 18th 2024Durga Borkar, MD, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss her presentation on Fas inhibition with ONL1204 for the Treatment of Geographic Atrophy and the first-time results From a Phase 1b study at the American Society of Retina Specialists meeting held in Stockholm, Sweden.
ASRS 2024: 72-Week results from phase 3 BALATON and COMINO trials
July 18th 2024Carl Danzig, MD, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss his presentation on the 72-Week results from the Phase 3 BALATON and COMINO trials at the American Society of Retina Specialists meeting held in Stockholm, Sweden.
ASRS 2024: Topics attendees are keeping an eye on
July 17th 2024Sydney M. Crago, Assistant Managing Editor of Ophthalmology Times and Modern Retina, spoke with attendees, who shared which topics they are most looking forward to discussing at the American Society of Retina Specialists (ASRS) meeting held in Stockholm, Sweden.
ASRS 2024: Differential artery-vein analysis in eyes with diabetic retinopathy
July 17th 2024Jennifer Lim, MD, FARVO, FASRS, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss her presentation on differential artery-vein analysis in eyes with diabetic retinopathy and improvements on the OCTA classification using artificial intelligence at the American Society of Retina Specialists meeting held in Stockholm, Sweden.
VLOG: NeuroOp Guru: Nonleaking CRF and SRF out of proportion to optic disc edema from IIH
July 12th 2024Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss nonleaking cystoid macular edema and subretinal fluid out of proportion to optic disc edema in idiopathic intracranial hypertension in the setting of optic atrophy.
VLOG: NeuroOp Guru: Unique case of 15-year-old who showed signs of meningioma in eye
July 6th 2024Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss a unique case of a 15-year-old who showed signs of meningioma with epithelial whirls and some psammoma bodies in the eye.
NHL ophthalmologist on eye injuries and eye health in professional sports
July 1st 2024Ashley Brissette, MD, MSc, FRCSC, team ophthalmologist for the New York Rangers sat down to talk about eye injuries in hockey and other professional sports, as well as advancements in prevention and treatment for the players.
IOP outcomes with intravitreal injection of aflibercept, 8mg and 2mg in patients with DME
June 3rd 2024Mark Barakat, MD, sat down with Ophthalmology Times to discuss intraocular pressure outcomes with intravitreal injection of aflibercept, 8mg and 2mg in patients with diabetic macular edema through week 48 of the phase 2/3 PHOTON trial.
A post hoc analysis of the phase 2/3 PHOTON trial
June 2nd 2024Sean Adrean, MD, FAAO, sat down with Ophthalmology Times to discuss a post hoc analysis of the phase 2/3 PHOTON trial and the outcomes of patients with DME and baseline BCVA of 20/50 or worse or 20/40 or better who were treated with aflibercept 8 mg and 2 mg.
Impact of baseline CRT on vision among patients with DME
June 1st 2024Deepak Sambhara, MD, sat down with Ophthalmology Times to discuss the impact of baseline central retinal thickness (CRT) on vision among patients with diabetic macular edema (DME), as a post hoc analysis of the phase 2/3 PHOTON trial.